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CorrespondenceThe role of soil exposure in asthma
prevention during neonatal periodTo the Editor:
We read with great interest the article titled ‘‘Soil exposure
modifies the gut microbiota and supports immune tolerance in a
mouse model’’ by Ottman et al.1 The study investigated the effect
and mechanism of soil exposure–induced immune tolerance.
However, soil exposure to adults might not be practical in asthma
treatment and prevention.
Exposure to newmicrobiota might induce activation of innated
and acquired immune system, which might lead to symptoms
indicating intestinal inflammation, such as diarrhea.2 Intestine
microbiota of people from different areas varies greatly, and
travel to a new area might cause traveler’s diarrhea.3 However,
Ottman et al1 did not show the pathology of intestine, severity
of diarrhea, hematochezia, and weight loss during soil exposure
and before sensitization and airway challenge in their study.
The immune tolerance effect of soil exposure might be caused
by rebalance of immunity and intestine microbiota.
The neonatal period is the most proper period for soil exposure.
Neonates were born to a relatively safe environment with
extensive safe antigens and little pathogens. Thus, one of the
major targets of the neonatal immune system is to build
immune tolerance to environmental antigens. Several
immune-suppressive cells have been found to induce immune
tolerance to environmental antigens.4 Soil exposure begins right
after birth for mammals, which might play a significant role in
immune tolerance and prevention of allergic diseases including
asthma.5 Thus, soil exposure should be a given for pregnant
mice and should remain persistent during the neonatal period,
which might lead to a more significant effect in reducing
ovalbumin-induced lung inflammation.
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We appreciate the interest from Jiang et al1 regarding our
article titled ‘‘Soil exposure modifies the gut microbiota and
supports immune tolerance in a mouse model.’’2 The readers’
first question addresses the induction of a possible pathology
in the intestines of the mice by the soil exposure. This is an
important question, and one that we did not fully consider in
the article.
Shifts in the composition of the gut microbiota, induced by, for
instance, a change in the diet, or invasive pathogens, can disturb
the balance of organisms and favor the outgrowth of potentially
pathogenic constituents.3 Traveling, for instance, involves
exposing oneself to foreign microbes, and acute diarrhea is the
most common travel-related condition, caused by bacterial, viral,
or protozoal pathogens. Globally, Escherichia coli is the most
common bacterial pathogen, followed by Campylobacter and
Shigella, members of the phylum Proteobacteria. In the soil-
exposed mice, we observed the enrichment of Proteobacteria,
compared with the controls. Investigation at the species level,
however, is hindered by the low taxonomic resolution provided
by 16s rRNA gene sequencing.
The readers ask whether we could show any pathology of the
intestine in the mice that were exposed to soil. Of note, most soil
organisms pose no risk to human health, but represent rather the
opposite: evidence is accumulating that soil biodiversity is of
great benefit, and only a small minority of species living in soils
can cause disease.4 Regarding the soil-exposed mice, at the time
of read-out, the mice appeared healthy and normally sized
compared with their counterparts that were raised in control
conditions. Moreover, we collected stool throughout the study,
and were therefore able to follow up on stool texture. We did
not observe any abnormalities, including diarrhea or
hematochezia. Unfortunately, we did not weigh the animals.
However, an important inclusion criterion in the experiment is
the continued well-being of the animals, including normal
feeding, drinking, and daily activities, a smooth fur, and normal
growth. Any signs of ill health would have led to exclusion of
the animal from the experiments.
Of note, the soil exposures in the mice started at a very young
age, 3 to 4 weeks old, and continued for 6 weeks, before exposure
to the asthma protocol. Presumably, this relatively long period of
time, at least from a mouse perspective, may have allowed for
adaptation to the colonization by new microbial species. This is
spoken for by our observations of gene expression profiles in the
ileum, finding no elevation in proinflammatory mediators in the
intestinal epithelium at the time of read-out.
The reader also points out that the neonatal period would be the
most proper period for interventions such as ours. In human
studies, the first years of life appear to be critical in this respect,5
and in animal models the timing of exposure relative to
sensitization is critical.6,7 However, our and others’ previous
work do also argue for the importance of a continued exposure
to beneficial microbiota, to maintain a homeostatic balance and
healthy immune responses.8,9
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https://doi.org/10.1016/j.jaci.2019.07.003Regulation of allergen immunotherapy
products in Europe and the
United StatesTo the Editor:
We read with interest the CME review article ‘‘Understanding
differences in allergen immunotherapy products and practices in
North America and Europe,’’1 in which the authors compare the
regulation of such products in Europe with their regulation in
the United States. Unfortunately, the authors inaccurately
describe the US regulatory framework for allergenic extracts.
Here is a partial list of errors:
1. The section titled ‘‘Regulation and Clinical Development of
New Products, US Regulatory Standards’’ includes a discussion
of the Food and Drug Administration’s (FDA’s) procedures for
classification/reclassification of allergenic extracts into category
I, II, IIIA, or IIIB. These procedures, formerly specified in
regulations (21 CFR 601.25 and 601.26) and rendered obsolete
in 2016, relate to allergenic extracts regulated by the National
Institutes of Health before transfer to the FDA in 1972 and
are irrelevant to regulation of new products. The authors also
omit that, consequent to the most recent review of these extracts,
the FDA revoked licenses for 15 extracts in 2013 because of
safety concerns.
2. The authors state, ‘‘There is no formal FDA guidance for
clinical development of [AIT products]. Each product under
development in the US is considered separately by the
CBER.’’ The authors communicate that, lacking a formal
guidance document, the FDA is unable to provide consistent,
proactive advice to manufacturers. This is untrue. The FDAroutinely provides pre- and post-licensure advice to
manufacturers, consistent with applicable regulations and
statutes. Furthermore, the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use (ICH) documents described in Table E2 as
European Union (EU) guidance documents are also considered
as part of FDA’s guidance regimen.
3. Fig 1 contrasts a detailed EU clinical development framework
with a superficial US framework that suggests, erroneously, that
the FDA requires non-US phase II data for review of new
products. This is untrue. Furthermore, the authors assert
(without reference) that ‘‘much [in the US regulations] has
been borrowed from EU precedents.’’ This is untrue as well.
Although US and EU regulators appropriately learn from the
other’s experiences, their frameworks for pharmaceutical
regulation evolved independently, the history of which is beyond
the scope of this letter.
4. The authors state, again without reference, that in the EU, ‘‘.
the pharmaceutical company has to provide evidence for
impeccable [emphasis added] quality, efficacy and safety’’ of
an allergenic product. The obvious implication is that US
standards for manufacturing allergenic extracts are inferior to
the EU standards. This is untrue. In the United States—no less
than in the EU—the standards for licensure include a
demonstration of safety, purity, and potency. Furthermore, the
word ‘‘impeccable’’ is an odd choice in this situation, which
implies perfection rarely attainable in science or regulation.
5. The authors state, ‘‘Only products with a positive benefit/risk
ratio [can be licensed in the EU].’’ Obviously, this is also a
requirement for US licensure.
In conclusion, rather than presenting a disinterested
comparison of EU and US regulatory practices, the authors
have substituted opinion for fact in an article that is inconsistent
with the standards of the Journal of Allergy and Clinical
Immunology, and inappropriate as a CME review.
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Reviewing such a broad topic is formidable given many
differences in extracts, manufacturing, clinical diagnoses,
treatments, and regulation of new product development.1 In our
attempt to present a concise review of differences between
continents, we did not intend to minimize the role of the US
Food and Drug Administration (FDA) in assuring quality, safety,
